Status:
COMPLETED
Topical Nicotinamide in Treatment of DLE
Lead Sponsor:
Al-Azhar University
Conditions:
Discoid Lupus Erythematosus
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin. There are 3 main types: Acute cutaneous lupus, Subacute cuta...
Detailed Description
DLE is the most common form of chronic cutaneous erythematosus and can occur as a localized form (80%) with lesions on the face, ears, and scalp or as disseminated DLE (20%) with lesions above and bel...
Eligibility Criteria
Inclusion
- Age: between 18 years and 65 years old
- Patients clinically and histopathologically newly diagnosed as DLE
- Patients clinically and histopathologically diagnosed with cutaneous lupus erythematosus that has not responded to treatment with hydroxychloroquine(200-400mg/day) plus corticosteroid at a dosage less than the equivalent of (0.5mg/kg/day) for the preceding two months or a longer period
Exclusion
- Age \< 18 years old
- Pregnant and lactating women
- A history of treatments with multivitamins in the recent month
- Soft tissue infection
- Severe comorbidities including heart failure, respiratory failure
- Acute severe infections such as cellulitis or a history of HBV or HCV
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05362188
Start Date
March 1 2022
End Date
September 30 2022
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AL-Azhar University Hospital
Cairo, Egypt, 11865